Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a price target of $26.00. Larry Biegelsen has given his Buy ...

“I’m optimistic,” Bausch + Lomb CEO Brent Saunders told STAT. Zach Weinberg, CEO of Curie.Bio, said that while Trump’s policies on health care have been known to shift, “R.F.K. is scary ...

Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

Bausch + Lomb scaled up its revenue guidance for the year after swinging to a profit in the latest quarter on the back of sales growth in each of its business segments.

Cathleen McCabe, MD has joined Bausch + Lomb as strategic medical advisor. Palvella Therapeutics named Matthew E. Korenberg as CFO. Disc Medicine appointed Rahul Kaushik as CTO. Inspire, an online ...

(Bloomberg) -- Banks and private credit firms are competing to provide at least $5 billion of debt financing to help fund a potential buyout of Bausch Lomb, according to people with knowledge of ...

According to the report, bondholders sought to restructure the company's debt to avoid filing for bankruptcy, which included an offer to swap some debt for equity in the Bausch + Lomb unit.

The company reports revenues under five segments — Salix, International, Diversified Products, Solta Medical and Bausch + Lomb. Salix revenues totaled $642 million, up 5% year over year.

to $10 from $8.50 and keeps a Sector Perform rating on the shares ahead of the company’s Q3 report due after market close on October 30 following Bausch + Lomb’s (BLCO) Q3 results due before ...